公开(公告)号：US09623098B2

公开(公告)日：2017-04-18

申请号：US12993693

申请日：2009-05-26

申请人： Sanjeev K. Mendiretta ,  Reinhard Glueck ,  Viviana Giannino ,  Giuseppina Cantarella ,  Francesca Scuderi ,  Martin Billeter ,  Agata Fazzio

发明人： Sanjeev K. Mendiretta ,  Reinhard Glueck ,  Viviana Giannino ,  Giuseppina Cantarella ,  Francesca Scuderi ,  Martin Billeter ,  Agata Fazzio

IPC分类号： A61K39/015 ,  A61K39/12 ,  A61K39/165 ,  A61K39/00

CPC分类号： A61K39/015 ,  A61K39/12 ,  A61K39/165 ,  A61K2039/5256 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/70 ,  C12N2710/20034 ,  C12N2760/18434 ,  C12N2760/18443

摘要： The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma. In a preferred embodiment, the combined vaccines are easy to produce on a large scale and can be distributed at low cost.

公开(公告)号：US20110129493A1

公开(公告)日：2011-06-02

申请号：US12993693

申请日：2009-05-26

申请人： Sanjeev K. Mendiretta ,  Reinhard Glueck ,  Viviana Giannino ,  Giuseppina Cantarella ,  Francesca Scuderi ,  Martin Billeter ,  Agata Fazzio

发明人： Sanjeev K. Mendiretta ,  Reinhard Glueck ,  Viviana Giannino ,  Giuseppina Cantarella ,  Francesca Scuderi ,  Martin Billeter ,  Agata Fazzio

IPC分类号： A61K39/295 ,  C12N15/63 ,  A61P31/14 ,  A61P31/20 ,  C12N5/10 ,  C12N1/21

CPC分类号： A61K39/015 ,  A61K39/12 ,  A61K39/165 ,  A61K2039/5256 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/70 ,  C12N2710/20034 ,  C12N2760/18434 ,  C12N2760/18443

摘要： The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma. In a preferred embodiment, the combined vaccines are easy to produce on a large scale and can be distributed at low cost.

摘要翻译： 本发明涉及针对麻疹和人乳头状瘤病毒（HPV）的组合疫苗。 特别地，本发明涉及包含编码由HPV衍生的单个或几个抗原的异源核酸的重组麻疹病毒载体，优选主要的capside抗原L1，次要的抗原L2，早期基因E6和HPV的早期基因E7癌蛋白 16型，以及任选的类型18,6和11.在第一个实施方案中，产生表达HPV抗原，优选L1和/或L2的预防性疫苗，使得它们在哺乳动物，优选人类中诱导有效的长效免疫应答 防止HPV和MV感染。 在另一个实施方案中，生成表达E6和E7蛋白以及任选的L1和L2的治疗性疫苗，使得它们诱导强的免疫应答将解决包括HPV诱导的宫颈癌在早期或晚期的持续性HPV感染。 在优选的实施方案中，组合的疫苗易于大规模生产并且可以以低成本分布。

公开(公告)号：US20070280961A1

公开(公告)日：2007-12-06

申请号：US11320487

申请日：2005-12-27

申请人： Martin Billeter ,  Pius Spielhofer ,  Karin Kalin ,  Frank Radecke ,  Henriette Schneider

发明人： Martin Billeter ,  Pius Spielhofer ,  Karin Kalin ,  Frank Radecke ,  Henriette Schneider

IPC分类号： A61K39/165 ,  A61K31/70 ,  A61P31/14 ,  A61P43/00 ,  C07H21/04 ,  C12N1/21 ,  C12N15/63 ,  C12N5/10 ,  C12N7/00 ,  C12N7/02

CPC分类号： C12N15/86 ,  A01N63/00 ,  A01N63/02 ,  A61K39/00 ,  A61K39/12 ,  A61K39/165 ,  A61K48/00 ,  A61K2039/51 ,  A61K2039/525 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/02 ,  C12N7/00 ,  C12N2760/18421 ,  C12N2760/18422 ,  C12N2760/18434 ,  C12N2760/18443 ,  C12N2760/20222 ,  C12N2760/20241 ,  C12N2840/203 ,  C12N2840/44

摘要： The present invention relates, in general, to a methodology or the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a model for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.

摘要翻译： 本发明一般涉及克隆的脱氧核糖核酸（cDNA）的方法或生成非分段负链RNA病毒（Pringle，1991）。 这种被拯救的病毒适合用作疫苗，或者作为体细胞基因治疗应用中的质粒。 本发明还涉及适合作为该方法中的工具的cDNA分子以及帮助直接拯救这些病毒的细胞系。 麻疹病毒（MV）被用作Mononegavirales的其他代表，特别是副粘病毒科的模型。